arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Bausch Health Companies Inc.

BHC
$5.65 ▼ -0.07 (-1.22%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
72 Visible periods
33 Metrics
Peer-ranked Benchmarks
Price Chart
57
Health
Fair
Moderately Bearish
auto_awesome

Analytical Summary

Bausch Health Companies Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $2.1B
Dividend Yield —
Revenue Growth 12.7% ↗
Op. Margin 25.9% ↗
ROIC 2.9% ↗
FCF / Share $1.58 ↗
Trailing P/E 8.2x
Price / Book —
FCF Yield 28.0%
Debt / Equity -11.71
info Valuation on last close. End-of-day price, Sep 24, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.85B
↑ +12.7% —
Net Income Profit after all expenses
$258.00M
↑ +74.3% —
Operating Margin Operating profit as % of sales
25.9%
↑ +168.9% 72th
FCF / Share Free cash flow per share
$1.58
↑ +387.2% —
Long-Term Debt Long-term obligations
$20.74B
— -0.1% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability →
56
Returns ↑
24
Financial Health ↑
77
Cash Quality
96

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 19 years · 72 quarters